ArticleAdvanced healthcare materials2026
Melt Electrowriting High Resolution Poly(ethylene-co-vinyl acetate) Scaffolds for Soft Tissue Engineering.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Melt electrowriting (MEW) holds tremendous potential to advance regenerative engineering, yet its clinical translation is hindered by the inability to replicate the biomechanics of soft tissues. We present, for the first time, MEW of polyethylene vinyl acetate (PEVA), demonstrating its potential as a highly compliant and biocompatible polymer for high-resolution scaffold fabrication. Optimized printing parameters displayed a highly stable jet, enabling microscale fibers to be fabricated with pore sizes down to 100 µm, achieving the highest diameter-to-spacing ratio reported to date for elastic MEW polymers. MEW PEVA fibers exhibited markedly enhanced mechanical compliance under tensile loading, with 4-fold and 35-fold greater compliance than thermoplastic polyurethane (TPU) and polycaprolactone (PCL), respectively, while maintaining yield strains comparable to TPU. Under compression, macroporous PEVA scaffolds showed an extended toe region of up to 75%, approximately 250-fold greater compliance than PCL, and yield strains exceeding 85%. PEVA scaffolds supported strong cell attachment and survival, with initial growth dynamics analogous to PCL and a significant increase in metabolic activity by day 7. This breakthrough establishes PEVA as a transformative material that overcomes the mechanical mismatch between MEW scaffolds and native soft tissues, expanding its translational potential for soft tissue engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.